Skip to main content

Table 3 Urinary prednisolone, prednisone, 20α-dihydroprednisolone and 20β-dihydroprednisolone concentrations during growth-promoting and therapeutic prednisolone treatment

From: Pharmacokinetic and urinary profiling reveals the prednisolone/cortisol ratio as a valid biomarker for prednisolone administration

  Prednisolone Prednisone 20α-dihydroprednisolone 20β-dihydroprednisolone
A1. Oral growth-promoting treatment
 N° positive 12 0 8 12
 Cmin (μg L−1) 0.027 - 0.153 0.695
 Cmax (μg L−1) 1.17 - 3.41 14.10
 Mean (μg L−1) 0.832 - 0.771 4.35
 SD (μg L−1) 0.381 - 0.544 2.44
A2. Intramuscular growth-promoting treatment
 N° positive 12 4 8 12
 Cmin (μg L−1) 0.014 0.030 0.138 0.938
 Cmax (μg L−1) 8.44 2.17 1.79 14.2
 Mean (μg L−1) 1.16 0.311 0.472 4.91
 SD (μg L−1) 1.08 0.413 0.308 3.15
B1. Oral therapeutic treatment
 N° positive 12 2 8 12
 Cmin (μg L−1) 0.038 0.033 0.156 1.07
 Cmax (μg L−1) 1.36 0.306 2.85 15.15
 Mean (μg L−1) 0.922 0.125 0.552 5.13
 SD (μg L−1) 0.428 0.108 0.635 1.20
B2. Intramuscular therapeutic treatment   
 N° positive 12 12 12 12
 Cmin (μg L−1) 0.528 1.08 3.32 8.97
 Cmax (μg L−1) 189 22.5 127 100
 Mean (μg L−1) 31.3 8.17 14.9 37.9
 SD (μg L−1) 40.7 5.91 26.0 25.0
  1. For each of the treatment set-ups (A1, A2, B1, B2), 12 bovines were considered. In case that a glucocorticoid was not found in the urine samples of all animals, means ± SD were determined based on the positive urine samples only